In a landmark decision for cardiac care, the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance to Cara Medical Ltd. for its CARA System. This platform is the first of its kind to provide noninvasive, patient-specific 3D visualization of the cardiac conduction system—the internal “electrical wiring” of the heart—using standard CT angiography (CTA) data.
This clearance follows the system’s “Breakthrough Device Designation” last year. It addresses a long-standing challenge in cardiology: seeing exactly where the conduction system lies during high-risk procedures like heart valve replacements.
Precision Guidance for Structural Heart Procedures
Currently, procedures like Transcatheter Aortic Valve Replacement (TAVR) carry a risk of damaging the heart’s electrical pathways, often resulting in the need for a permanent pacemaker. The CARA System aims to mitigate this by providing a “GPS” for the heart’s electrical axis.
The system consists of two integrated platforms:
- CARA Metis™ Simulator: A pre-procedural software that uses AI/ML-based algorithms to map the patient’s conduction system from CT scans.
- CARA Atlas™ Navigator: An intra-procedural tool that overlays this 3D map onto live fluoroscopic (X-ray) images, allowing doctors to “see” the electrical pathways in real-time.
Key Applications in 2026
The CARA System is designed to integrate seamlessly into existing hospital workstations and fluoroscopy systems without requiring direct patient contact.
- TAVR and Valve Interventions: Assists surgeons in placing valves without compressing or damaging the conduction system.
- Conduction System Pacing (CSP): Facilitates the precise placement of pacemaker leads into the heart’s natural electrical bundles for more “physiologic” or natural heartbeats.
- Future Expansion: The company is also targeting Transcatheter Mitral (TMVR) and Tricuspid (TTVR) valve replacements.
“This FDA clearance represents a significant milestone… providing physicians with a validated tool designed to enhance visualization of the cardiac conduction axis.” — Shlomo Ben-Haim, MD, Founder and Chairman of Cara Medical.
Editorial Disclosure: This article combines final reporting with the required disclosure. This report is for informational purposes only and is based on a press release from Cara Medical Ltd. dated February 25, 2026. This content does not constitute medical or professional advice. The CARA System is a tool for physician guidance; all clinical decisions remain the responsibility of the treating medical professional. Please read our full Disclaimer.
